[et_pb_section fb_built=”1″ fullwidth=”on” disabled_on=”off|off|off” admin_label=”milner_rules” _builder_version=”3.22″ custom_padding=”0px||0px|” transparent_background=”off”][et_pb_fullwidth_image src=”https://www.milner.cam.ac.uk/wp-content/uploads/2017/09/rule.jpg” disabled_on=”on|on|off” _builder_version=”3.0.87″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”0px|||” animation_direction=”off” animation=”off” border_style=”solid”][/et_pb_fullwidth_image][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”4.3.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_divider show_divider=”off” admin_label=”Divider” module_id=”labs” module_class=”labs” _builder_version=”4.5.3″][/et_pb_divider][et_pb_text admin_label=”COMPANIES AND ACADEMICS IN RESIDENCE” module_id=”labs” _builder_version=”4.6.6″ text_font=”|on||on|” text_text_color=”#ff9900″ text_letter_spacing=”3px” header_font=”|on||on|” header_letter_spacing=”3px” hover_enabled=”0″ z_index_tablet=”500″ border_style=”solid” sticky_enabled=”0″ header_text_color=”#253647″]
COMPANIES AND ACADEMICS IN RESIDENCE
[/et_pb_text][et_pb_text admin_label=”Overview” _builder_version=”4.6.6″ header_font_size=”36px” header_line_height=”1.5em” z_index_tablet=”500″ text_text_shadow_horizontal_length_tablet=”0px” text_text_shadow_vertical_length_tablet=”0px” text_text_shadow_blur_strength_tablet=”1px” link_text_shadow_horizontal_length_tablet=”0px” link_text_shadow_vertical_length_tablet=”0px” link_text_shadow_blur_strength_tablet=”1px” ul_text_shadow_horizontal_length_tablet=”0px” ul_text_shadow_vertical_length_tablet=”0px” ul_text_shadow_blur_strength_tablet=”1px” ol_text_shadow_horizontal_length_tablet=”0px” ol_text_shadow_vertical_length_tablet=”0px” ol_text_shadow_blur_strength_tablet=”1px” quote_text_shadow_horizontal_length_tablet=”0px” quote_text_shadow_vertical_length_tablet=”0px” quote_text_shadow_blur_strength_tablet=”1px” header_text_shadow_horizontal_length_tablet=”0px” header_text_shadow_vertical_length_tablet=”0px” header_text_shadow_blur_strength_tablet=”1px” header_2_text_shadow_horizontal_length_tablet=”0px” header_2_text_shadow_vertical_length_tablet=”0px” header_2_text_shadow_blur_strength_tablet=”1px” header_3_text_shadow_horizontal_length_tablet=”0px” header_3_text_shadow_vertical_length_tablet=”0px” header_3_text_shadow_blur_strength_tablet=”1px” header_4_text_shadow_horizontal_length_tablet=”0px” header_4_text_shadow_vertical_length_tablet=”0px” header_4_text_shadow_blur_strength_tablet=”1px” header_5_text_shadow_horizontal_length_tablet=”0px” header_5_text_shadow_vertical_length_tablet=”0px” header_5_text_shadow_blur_strength_tablet=”1px” header_6_text_shadow_horizontal_length_tablet=”0px” header_6_text_shadow_vertical_length_tablet=”0px” header_6_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px”]
Selected start-up companies, and junior academic research groups whose research interests are aligned with ours, are housed in the Centre for Pathway Analysis. Our Milner Therapeutics Consortium pharma partners also have a physical presence, through scientists working on collaborative projects with Cambridge researchers and through hot-desking.
Rockend Ltd, a start-up company working on the application of stem cell technology towards new therapies, is currently based at the Milner Therapeutics Institute and current academics in residence are:
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.6.6″ _module_preset=”default” custom_padding=”||0px||false|false” hover_enabled=”0″ sticky_enabled=”0″][et_pb_column _builder_version=”4.6.6″ _module_preset=”default” type=”4_4″][et_pb_text _builder_version=”4.6.6″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]
KOSTAS TZELEPIS
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row column_structure=”3_4,1_4″ _builder_version=”4.6.6″ _module_preset=”default” hover_enabled=”0″ custom_padding=”2px||||false|false” sticky_enabled=”0″][et_pb_column type=”3_4″ _builder_version=”4.5.3″ _module_preset=”default”][et_pb_text admin_label=”Tzelepis” _builder_version=”4.6.6″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]
The Tzelepis group (Milner Therapeutics Institute and Wellcome Sanger Institute) is uncovering epigenetic mechanisms that are implicated in devastating malignancies including acute myeloid leukaemia (AML). His work previously identified several novel RNA-binding/modifying proteins that are essential for AML cell survival, including the RNA methyltransferase METTL3 and the splicing kinase SRPK1. Now, the group is investigating the role of RNA modifications and splicing in cancer initiation and maintenance. As part of the Centre for Pathway Analysis, Kostas will bring vital know-how in both the design of CRISPR screening for improved disease understanding, and also the development of sophisticated in vivo and in vitro assays for genetic and pharmacological validation of promising targets.
[/et_pb_text][/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.5.3″ _module_preset=”default”][et_pb_blurb title=”Dr Kostas Tzelepis” url=”mailto: k.tzelepis@milner.cam.ac.uk” image=”https://nikkitest.space/wp-content/uploads/2020/11/Tzelepis.png” alt=”Tony Kouzarides” admin_label=”Dr Kostas Tzelepis” _builder_version=”4.6.6″ header_font=”|on|||” header_text_align=”center” header_font_size=”14″ body_font_size=”12″ body_line_height=”1.4em” background_color=”rgba(39,54,69,0.11)” text_orientation=”center” module_alignment=”center” custom_padding=”10px|10px|10px|10px” animation=”off” link_option_url=”mailto: k.tzelepis@milner.cam.ac.uk” hover_enabled=”0″ border_color=”#414444″ border_style=”solid” saved_tabs=”all” locked=”off” sticky_enabled=”0″ title_text=”Tzelepis”][/et_pb_blurb][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.6.6″ _module_preset=”default” custom_padding=”||0px||false|false” hover_enabled=”0″ sticky_enabled=”0″][et_pb_column _builder_version=”4.6.6″ _module_preset=”default” type=”4_4″][et_pb_text _builder_version=”4.6.6″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]
MANAV PATHANIA
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row column_structure=”3_4,1_4″ _builder_version=”4.6.6″ _module_preset=”default” hover_enabled=”0″ custom_padding=”2px||||false|false” sticky_enabled=”0″][et_pb_column type=”3_4″ _builder_version=”4.5.3″ _module_preset=”default”][et_pb_text admin_label=”MANAV PATHANIA” _builder_version=”4.6.6″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]
The Pathania group (Milner Therapeutics Institute, Dept Oncology and CRUK Cambridge Centre) have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis of different brain tumour types. By applying CRISPR technology to test genetic and epigenetic weaknesses in these tumour models, they hope in the longer term to pave the way to more targeted, precise treatments that can be tailored to each patient. A key area of interest includes how dynamic chromatin remodelling is regulated in neural stem cells and how it becomes co-opted in brain cancer, including paediatric high-grade glioma.
[/et_pb_text][/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.5.3″ _module_preset=”default”][et_pb_blurb title=”Dr Manav Pathania” url=”mailto: k.tzelepis@milner.cam.ac.uk” image=”https://nikkitest.space/wp-content/uploads/2020/11/MP.png” alt=”Tony Kouzarides” admin_label=”Dr Manav Pathania” _builder_version=”4.6.6″ header_font=”|on|||” header_text_align=”center” header_font_size=”14″ body_font_size=”12″ body_line_height=”1.4em” background_color=”rgba(39,54,69,0.11)” text_orientation=”center” module_alignment=”center” custom_padding=”10px|10px|10px|10px” animation=”off” link_option_url=”mailto: k.tzelepis@milner.cam.ac.uk” hover_enabled=”0″ border_color=”#414444″ border_style=”solid” saved_tabs=”all” locked=”off” sticky_enabled=”0″ title_text=”MP”][/et_pb_blurb][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ fullwidth=”on” disabled_on=”on|on|on” _builder_version=”3.22″ disabled=”on”][et_pb_fullwidth_image src=”https://www.milner.cam.ac.uk/wp-content/uploads/2017/09/mil_full_image_4.jpg” _builder_version=”3.0.87″ border_style=”solid”][/et_pb_fullwidth_image][/et_pb_section]